Live Breaking News & Updates on Month Topline Data

Stay updated with breaking news from Month topline data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Ocular Therapeutix™ Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD

Ocular Therapeutix™ Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Park City , Antony Mattessich , Arshadm Khanani , Rabia Gurses Ozden , Peterk Kaiser , Mediaicr Westwickeben Shannon , Icr Westwickechris Brinzey , Clinical Research At Sierra Eye Associates , Exchange Commission , Ocular Therapeutix Inc , Retinal Pharmaceuticals Market , Clinical Research , Sierra Eye Associates , Clinical Trials , Chief Executive Officer , Month Topline Data , Trial Evaluating , Chief Medical Officer , Ocular Therapeutix , Chief Medical Advisor , Retinal Pharmaceuticals Market Report , Private Securities Litigation Reform Act , Therapeutixdonald Notmanchief Financial Officer , Chris Brinzey , Ben Shannon ,

Ocular Therapeutix™ Announces 12-Month Topline Data from

OTX-TKI maintained vision and CSFT comparable to aflibercept every eight weeks, with 89% reduction in treatment burden over a 12-month period OTX-TKI. ....

United States , Park City , Rabia Gurses Ozden , Chris Brinzey , Antony Mattessich , Ben Shannon , Arshadm Khanani , Peterk Kaiser , Donald Notman , Ocular Therapeutix Inc , Retinal Pharmaceuticals Market , Clinical Research At Sierra Eye Associates , Exchange Commission , Clinical Research , Sierra Eye Associates , Clinical Trials , Chief Executive Officer , Month Topline Data , Trial Evaluating , Chief Medical Officer , Ocular Therapeutix , Chief Medical Advisor , Retinal Pharmaceuticals Market Report , Private Securities Litigation Reform Act ,